Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
AXSM Axsome Therapeutics, Inc. daily Stock Chart
AXSM [NASD]
Axsome Therapeutics, Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E- EPS (ttm)-1.37 Insider Own2.10% Shs Outstand32.87M Perf Week4.81%
Market Cap924.63M Forward P/E- EPS next Y-1.28 Insider Trans5.63% Shs Float25.35M Perf Month8.15%
Income-42.30M PEG- EPS next Q-0.39 Inst Own53.40% Short Float23.88% Perf Quarter16.38%
Sales- P/S- EPS this Y9.40% Inst Trans25.33% Short Ratio7.27 Perf Half Y116.38%
Book/sh0.72 P/B39.07 EPS next Y12.90% ROA-129.90% Target Price36.83 Perf Year793.02%
Cash/sh1.64 P/C17.19 EPS next 5Y- ROE-390.30% 52W Range1.94 - 30.50 Perf YTD897.52%
Dividend- P/FCF- EPS past 5Y-56.60% ROI- 52W High-7.77% Beta2.62
Dividend %- Quick Ratio4.20 Sales past 5Y- Gross Margin- 52W Low1350.00% ATR1.63
Employees37 Current Ratio4.20 Sales Q/Q- Oper. Margin- RSI (14)58.68 Volatility7.30% 5.83%
OptionableYes Debt/Eq0.81 EPS Q/Q-26.80% Profit Margin- Rel Volume0.94 Prev Close27.37
ShortableYes LT Debt/Eq0.72 EarningsAug 08 BMO Payout- Avg Volume832.38K Price28.13
Recom1.50 SMA209.63% SMA509.76% SMA20067.88% Volume783,072 Change2.78%
Sep-18-19Initiated William Blair Outperform
May-28-19Initiated SunTrust Buy
May-23-19Reiterated H.C. Wainwright Buy $23 → $30
Apr-08-19Initiated SVB Leerink Outperform $25
Mar-15-19Reiterated H.C. Wainwright Buy $15 → $18
Oct-03-16Resumed Brean Capital Buy
Dec-15-15Initiated Cantor Fitzgerald Buy
Dec-14-15Initiated Ladenburg Thalmann Buy
Sep-18-19 02:08PM  Axsome Shares Flirt With Record High: How Much Upside Is Left? Benzinga
Sep-04-19 01:25PM  How Much Are Axsome Therapeutics, Inc. (NASDAQ:AXSM) Insiders Spending On Buying Shares? Simply Wall St.
Sep-03-19 07:00AM  Axsome Therapeutics to Present at the Morgan Stanley 17th Annual Global Healthcare Conference GlobeNewswire
Aug-31-19 01:19AM  Edited Transcript of AXSM earnings conference call or presentation 8-Aug-19 12:00pm GMT Thomson Reuters StreetEvents
Aug-29-19 08:58AM  Is the Options Market Predicting a Spike in Axsome (AXSM) Stock? Zacks
Aug-20-19 07:00AM  Axsome Therapeutics Appoints David Marek as Chief Commercial Officer GlobeNewswire
Aug-09-19 11:52AM  Axsome Therapeutics, Inc. (AXSM) Q2 2019 Earnings Call Transcript Motley Fool
Aug-08-19 07:00AM  Axsome Therapeutics Reports Second Quarter 2019 Financial Results and Provides Business Update GlobeNewswire
Jul-30-19 07:00AM  Axsome Therapeutics To Report Second Quarter 2019 Financial Results On August 8, 2019 GlobeNewswire
Jul-29-19 07:00AM  Axsome Therapeutics Amends Silicon Valley Bank Loan Agreement Increasing Financial Flexibility GlobeNewswire
Jul-16-19 07:46PM  About to Buy Penny Stocks? Look at These 3 Companies First Motley Fool
Jul-12-19 08:50AM  Implied Volatility Surging for Axsome (AXSM) Stock Options Zacks
07:15AM  5 Best Biotech Stocks of 2019 So Far Motley Fool
Jul-07-19 11:07AM  Here's Why Axsome Therapeutics Stock Rocketed 813% in the First Half of 2019 Motley Fool
Jul-02-19 07:29AM  The Daily Biotech Pulse: Celyad To Advance Leukemia Drug To Clinical Trial, Positive Data For Teva's Migraine Drug Benzinga
Jul-01-19 07:00AM  Axsome Therapeutics Added to Russell 3000® and Russell 2000® Indexes GlobeNewswire
Jun-26-19 06:28PM  Hedge Funds Have Never Been This Bullish On Axsome Therapeutics, Inc. (AXSM) Insider Monkey -6.46%
Jun-25-19 04:19PM  Axsome Initiates Phase III Study on Depression Candidate Zacks
Jun-24-19 07:00AM  Axsome Therapeutics Initiates GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder GlobeNewswire
Jun-20-19 11:11AM  3 Stocks the World's Best Investors Are Buying Right Now Motley Fool
Jun-07-19 07:00AM  Axsome Therapeutics Provides Update on Continued Progress at Annual Stockholders Meeting GlobeNewswire
Jun-05-19 10:45AM  Do Institutions Own Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares? Simply Wall St. -8.96%
Jun-04-19 07:24AM  3 Top Small-Cap Stocks to Buy in June Motley Fool
May-21-19 07:00AM  Axsome Therapeutics To Present Data From ASCEND Phase 2 Trial Of AXS-05 In Major Depressive Disorder At The 2019 American Society For Clinical Psychopharmacology Annual Meeting GlobeNewswire
May-20-19 12:48PM  These 3 Small-Cap Healthcare Stocks Reported Big Updates This Month Motley Fool
May-19-19 09:19AM  Here's Why You'll Regret Ignoring This Biotech Stock Rocket Motley Fool
May-10-19 01:48PM  Edited Transcript of AXSM earnings conference call or presentation 9-May-19 12:00pm GMT Thomson Reuters StreetEvents +6.26%
May-09-19 10:59PM  Axsome Therapeutics, Inc. (AXSM) Q1 2019 Earnings Call Transcript Motley Fool
07:25AM  Axsome: 1Q Earnings Snapshot Associated Press
07:00AM  Axsome Therapeutics Reports First Quarter 2019 Financial Results and Provides Business Update GlobeNewswire
May-08-19 02:30PM  Harry Boxers four stocks to watch include cybersecurity company Carbon Black MarketWatch
12:22PM  4 Stocks Breaking Out On Earnings & Other News Benzinga
09:27AM  Small-Cap Stocks to Watch in May Motley Fool
09:23AM  What's in the Cards for Fuel Tech (FTEK) in Q1 Earnings? Zacks
May-07-19 04:54PM  What's in Store for Axsome (AXSM) This Earnings Season? Zacks
May-06-19 03:01PM  Axsome Shares Rally After FDA OKs Expedited Regulatory Filings For Depression Drug Benzinga +6.69%
07:00AM  Axsome Therapeutics Announces Acceleration of MOMENTUM Phase 3 Trial of AXS-07 in Migraine GlobeNewswire
06:30AM  Axsome Therapeutics Announces Expedited Development and Pivotal Status for AXS-05 in the Treatment of Major Depressive Disorder based on FDA Breakthrough Therapy Meeting GlobeNewswire
Apr-29-19 07:00AM  Axsome Therapeutics To Report First Quarter 2019 Financial Results On May 9, 2019 GlobeNewswire
Apr-25-19 09:23AM  2 Ultra-High Growth Stocks to Buy Now Motley Fool
Apr-17-19 07:48AM  Biotech Stock Roundup: GILD Collaborates on NASH, FCSC Surges on Deal Zacks
Apr-16-19 11:07AM  Axsome's AXS-05 Meets Goal in Phase II Study, Shares Up Zacks +8.18%
Apr-15-19 06:00AM  Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in Phase 2 Trial in Smoking Cessation GlobeNewswire +6.32%
Apr-08-19 09:19AM  Here's Why Axsome Therapeutics Rocketed 78.8% Higher in March Motley Fool
Apr-07-19 06:00PM  3 Stocks That Have More Than Tripled So Far in 2019 Motley Fool
Apr-03-19 08:50AM  Implied Volatility Surging for Axsome Therapeutics (AXSM) Stock Options Zacks
Mar-30-19 12:00PM  3 Leading Alzheimer's Disease Drugs in Development After Biogen's Aducanumab Flop Motley Fool
Mar-28-19 06:10PM  Axsome's Depression Drug Gets Breakthrough Therapy Status Zacks
09:49AM  3 Small Biotech Stocks Hitting New Highs Investopedia
07:27AM  Jim Cramer Weighs In On General Electric, Nio, Sprint And More Benzinga
Mar-27-19 08:22AM  UPDATE: Axsome Therapeutics shares soar after FDA grants breakthrough designation to depression drug MarketWatch
07:00AM  Axsome Therapeutics Receives FDA Breakthrough Therapy Designation for AXS-05 for the Treatment of Major Depressive Disorder GlobeNewswire
Mar-25-19 02:15PM  Here's Why Axsome Therapeutics' Stock Gained as Much as 22.9% Today Motley Fool +25.69%
11:51AM  Have Insiders Been Buying Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares This Year? Simply Wall St.
Mar-22-19 11:39AM  Harry Boxer: 3 biotech stocks with momentum MarketWatch
Mar-14-19 07:26AM  Axsome: 4Q Earnings Snapshot Associated Press
07:00AM  Axsome Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update GlobeNewswire
Mar-07-19 06:03AM  2 Biotech Stocks With Major Incoming Catalysts Motley Fool
Mar-06-19 07:00AM  Axsome Therapeutics Secures $24 Million Growth Capital Loan Facility Led by Silicon Valley Bank GlobeNewswire
Mar-05-19 07:00AM  Axsome Therapeutics to Report Fourth Quarter and Full Year 2018 Financial Results on March 14, 2019 GlobeNewswire
Mar-04-19 07:00AM  Axsome Therapeutics Initiates MOMENTUM Phase 3 Trial of AXS-07 in Migraine GlobeNewswire
Feb-06-19 07:00AM  Axsome Therapeutics Receives FDA Agreement under Special Protocol Assessment (SPA) for the MOMENTUM Phase 3 Trial of AXS-07 in Migraine GlobeNewswire -5.42%
Jan-30-19 07:00AM  Axsome Therapeutics Initiates Phase 2 Trial of AXS-12 in Narcolepsy GlobeNewswire
Jan-15-19 08:00PM  3 Small-Cap Stocks With Big-Cap Potential Motley Fool
Jan-10-19 01:38PM  Is This Why Axsome Therapeutics Is Losing Ground Again Today? Motley Fool
Jan-09-19 07:00AM  Market Rally Extends to Biotech ACCESSWIRE -14.98%
06:30AM  This Stock Generated 25X Returns In Just Five Years: Could BTCY Be At The Same Crossroads? ACCESSWIRE
Jan-08-19 12:38PM  Here's Why Axsome Therapeutics Has Been a Rocket Ship This Week Motley Fool +29.26%
10:17AM  Axsome Therapeutics: Do Not Buy AXSM Stock After Its Monster Rally InvestorPlace
09:15AM  Portfolios Making Up For Lost Time Zacks
08:30AM  The Next Big Biotech Breakout ACCESSWIRE
08:15AM  The Daily Biotech Pulse: Amgen Slashes Cholesterol Drug Device Prices By 60%, Takeda Completes Shire Purchase Benzinga
Jan-07-19 06:35PM  Axsome Therapeutics Raises $23.3 Million Under Existing ATM Facility GlobeNewswire +161.22%
01:28PM  AXSM News: Why Axsome Therapeutics Stock Is Skyrocketing Today InvestorPlace
12:25PM  4 Healthcare Stocks Making Moves On Monday (1/7/19) ACCESSWIRE
08:25AM  Tiny Pharma Company Surges 160% on Positive Depression Drug Data Bloomberg
08:23AM  Axsome's stock nearly triples on heavy volume after positive trial of depression treatment MarketWatch
06:00AM  Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in Phase 2 Trial in Major Depressive Disorder GlobeNewswire
Dec-31-18 01:50PM  These 4 Healthcare Stocks May Test December Highs ACCESSWIRE +29.36%
07:25AM  New Research: Key Drivers of Growth for Trimble, Maxar Technologies, MagnaChip Semiconductor, Palo Alto Networks, AAR, and Axsome Therapeutics Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Dec-27-18 10:25AM  These 4 Healthcare Stocks Are Gaining Speed ACCESSWIRE
07:00AM  Axsome Therapeutics Provides Year End 2018 Clinical Update GlobeNewswire
Dec-18-18 07:00AM  Axsome Therapeutics to Present at Biotech Showcase 2019 GlobeNewswire
Dec-11-18 06:55AM  Today's Research Reports on Trending Tickers: Axsome Therapeutics and Avid Bioservices ACCESSWIRE
Dec-10-18 08:25AM  UPDATE: Axsome Therapeutics shares soar 24% premarket on positive trial of Alzheimer's therapy MarketWatch +14.92%
07:00AM  Axsome Therapeutics Announces Positive Outcome of Interim Analysis of ADVANCE-1 Phase 2/3 Trial of AXS-05 in Alzheimers Disease Agitation GlobeNewswire
Nov-27-18 07:00AM  Axsome Therapeutics Expands Loan Agreement with Silicon Valley Bank Providing Additional Growth Capital Related to AXS-12 Product Candidate GlobeNewswire
Nov-21-18 08:50AM  Market Trends Toward New Normal in Wilhelmina International, Eyenovia, aTyr Pharma, Avinger, Viacom, and Axsome Therapeutics Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Nov-19-18 07:00AM  Axsome Therapeutics to Participate in 2018 Global Mizuho Investor Conference GlobeNewswire +9.22%
Nov-14-18 07:00AM  Axsome Therapeutics Announces Completion of Patient Enrollment in the ASCEND Phase 2 Trial of AXS-05 in Major Depressive Disorder GlobeNewswire
Nov-09-18 07:42AM  Axsome: 3Q Earnings Snapshot Associated Press
07:00AM  Axsome Therapeutics Reports Third Quarter 2018 Financial Results and Provides Business Update GlobeNewswire
Nov-01-18 07:00AM  Axsome Therapeutics to Report Third Quarter 2018 Financial Results on November 9, 2018 GlobeNewswire
Oct-18-18 07:00AM  Axsome Therapeutics Hosts R&D Day Today with Key Opinion Leaders Focusing on AXS-05 and Unmet Needs in Alzheimers Disease Agitation GlobeNewswire
Oct-17-18 07:00AM  Axsome Therapeutics Receives FDA Orphan Drug Designation for AXS-12 for the Treatment of Narcolepsy GlobeNewswire +11.36%
Oct-16-18 07:05AM  Axsome Therapeutics to Host Call Today with Key Opinion Leader Focusing on AXS-12 and Unmet Needs in Narcolepsy GlobeNewswire +5.07%
07:00AM  Axsome Therapeutics Announces AXS-12 for the Treatment of Narcolepsy GlobeNewswire
Oct-12-18 07:00AM  Axsome Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Oct-11-18 07:00AM  Axsome Therapeutics to Focus on Growing Core CNS Portfolio; Establishes Axsome Pain and Primary Care Business Unit to Enhance Value of Non-CNS Assets GlobeNewswire
Sep-28-18 07:00AM  Axsome Therapeutics Announces $8.9 Million Registered Direct Offering GlobeNewswire
Axsome Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05, which is in the Phase III clinical trial for the treatment resistant depression; Phase II/III clinical trials in agitation associated with Alzheimer's disease; and Phase II clinical trial for the treatment of smoking cessation, as well as for major depressive disorder. The company is also developing AXS-07, which is in Phase III clinical trial for the treatment of migraine; AXS-12 that is in Phase II clinical trial for the treatment of in narcolepsy; AXS-09, which has completed Phase I clinical trial for the treatment of various CNS disorders; and AXS-02, which is in Phase III clinical trial for the treatment of the pain of knee osteoarthritis associated with bone marrow lesions, and for the treatment of chronic low back pain associated with Modic changes. In addition, it is developing AXS-06 that has completed Phase I clinical trial for the treatment of osteoarthritis and rheumatoid arthritis and for the reduction of the risk of nonsteroidal anti-inflammatory drug associated gastrointestinal ulcers. The company has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase II trial in smoking cessation. The company was founded in 2012 and is based in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
JEFFS ROGERDirectorJul 03Option Exercise3.0456,620172,17856,620Jul 05 07:00 AM
Coleman MarkDirectorJun 26Buy23.1015,800364,980668,848Jun 27 07:18 AM
Coleman MarkDirectorJun 25Buy23.254009,300653,048Jun 27 07:18 AM
Pizzie NickChief Financial OfficerJun 11Buy20.801,92039,9361,920Jun 12 07:00 AM
Saad Mark EDirectorMay 23Buy22.333,50078,1557,002May 24 07:19 AM
Coleman MarkDirectorMay 13Buy21.444,65099,696652,648May 15 07:21 AM
Coleman MarkDirectorMar 19Buy12.185,10062,1185,100Mar 21 07:05 AM
Pizzie NickChief Financial OfficerMar 19Buy12.696076160Mar 21 07:05 AM
Pizzie NickChief Financial OfficerMar 19Buy12.585,34067,17736,340Mar 21 07:05 AM
open in yahoo | open in reuters | open in google